Use of Large Fascia Lata Graft as Dural Substitute in Neurosurgical Procedures at Neurosurgery Department Teaching Hospital D G Khan
Keywords:CSF Fistula,, Dural Repair
Introduction: Allogeneic grafts and other synthetic materials are being successfully used in dural grafting procedures. However, autologous resources including temporoparietal fascia, pericranium, peritoneum, and fascia lata provide an alternate substitute.' The use of fascia lata is the source of choice especially when large tissue is needed.
Materials and Methods: We present 21 cases 24 (75%) male, 7 (25%) female patients (age between 10 to 60 years) in which fascia lata was used for dural substitute when there was inadequate regional tissue, such as pericranium or temporalis fascia to repair the dural defect from May 2014 to April 2015, were analyzed retrospectively. Operative indications included in gunshot wound &head trauma 14 patients (50%), tumor in eight (28.5%), cerebrospinal fluid fistula in four (14.5%), infection in two (7.0%). This was a retrospective study and ethical approval was obtained from institutional ethical board. Department of Neurosurgery treated twenty eight patients in which fascia lata was used for dural substitute when there was inadequate regional tissue, such as pericranium or temporalis fascia to repair the dural defect from May 2014 to April 2016.
Results: The grafts' dimensions were from 4 × 8 cm to 8 × 18 cm. Clinical and radiologic follow-up was perfor-med up to year after surgery. There were very limited significant complications related to the fascia lata grafting (in terms of cerebrospinal fluid leakage, meningitis, and wound infection. Two patients presented post-operative CSF leakage and were treated by percutaneous lumbar drainage. All patients improved completely, requiring no additional treatment. In few cases infection was either systemic or local, but required long-term and broad-spectrum antibiotic regimen.
Conclusion: Fascia lata is relatively simple and effective dural substitute for larger defects without any significant complications in our patients.
2. Weller RO. Microscopic morphology and histology of the human meninges. Morphologie. 2005; 89: 22-34.
3. Spector JA, Greenwald JA, Warren SM, Bouletreau PJ, Detch RC, Fagenholz PJ, et al. Dura mater biology: autocrine and paracrine effects of fibroblast growth fac-tor 2. Plast Reconstr Surg. 2002; 109: 645-54.
4. Bartosz DK, Vasterling MK. Dura mater substitutes inthe surgical treatment of meningiomas. J Neurosci Nurs. 1994; 26: 140-5. 5. Update: Creutzfeldt – Jakob disease associated with cadaveric dura mater grafts – Japan, 1978 – 2008. MMWR Morb Mortal Wkly Rep. 2008; 57: 1152-4. 6. Nazzaro JM, Craven DE. Successful treatment of post-operative meningitis due to Haemophilus influenzae without removal of an expanded polytetrafluoroethy-lene dural graft. Clin Infect Dis. 1998; 26: 516-8. 7. Ito H, Kimura T, Sameshima T, Aiyama H, Nishimura K, Ochiai C, et al. Reinforcement of pericranium as a dural substitute by fibrin sealant. Acta Neurochir (Wien). 2011; 153: 2251-4. 8. Giovanni S, Della Pepa GM, La RG, Lofrese G, Alba-nese A, Maria G, et al. Galea-pericranium dural clo-sure: can we safely avoid sealants? Clin Neurol Neuro-surg. 2014; 123: 50-4. 9. von Wild KR. Examination of the safety and efficacy of an absorbable dura mater substitute (Dura Patch) in normal applications in neurosurgery. Surg Neurol. 1999; 52: 418-24. 10. Malliti M, Page P, Gury C, Chomette E, Nataf F, Roux FX. Comparison of deep wound infection rates using a synthetic dural substitute (neuro-patch) or pericranium graft for dural closure: a clinical review of 1 year. Neu-rosurgery, 2004; 54: 599-603. 11. Sabatino G, Della Pepa GM, Bianchi F, Capone G, Rig-ante L, Albanese A, et al. Autologous dural substitutes: a prospective study. Clin Neurol Neurosurg. 2014; 116: 20-3. 12. Huang YH, Lee TC, Chen WF, Wang YM. Safety of the nonabsorbable dural substitute in decompressive craniectomy for severe traumatic brain injury. J Tra-uma. 2011; 71: 533-7. 13. Gazzeri R, Galarza M, Alfieri A, Neroni M, Roperto R. Simple intraoperative technique for minor dural gap repair using fibrin glue and oxidized cellulose. World Neurosurg. 2011; 76: 1735.
14. Elstner KE, Clarke FK, Turner SJ. Case report: mana-gement of persistent dural anastomotic dehiscence in a patient treated with bevacizumab. Ann Plast Surg. 2013; 71: 652-3.
15. Chiang HY, Kamath AS, Pottinger JM, Greenlee JD, Howard MA, III, Cavanaugh JE, et al. Risk factors and outcomes associated with surgical site infections after craniotomy or craniectomy. J Neurosurg. 2014; 120: 509-21.
16. Clark AJ, Butowski NA, Chang SM, Prados MD, Cla-rke J, Polley MY, et al. Impact of bevacizumab chemo-therapy on craniotomy wound healing. J Neurosurg. 2011; 114: 1609-16.
17. Nishioka H, Haraoka J, Ikeda Y. Risk factors of cerebrospinal fluid rhinorrhea following transsphenoi-dal surgery. Acta Neurochir (Wien). 2005; 147: 1163-6.
18. Krishnan KG, Muller A, Hong B, Potapov AA, Scha-ckert G, Seifert V, et al. Complex wound-healing prob-lems in neurosurgical patients: risk factors, grading and treatment strategy. Acta Neurochir (Wien). 2012; 154: 541-54. 19. Boudreaux B, Zins JE. Treatment of cerebrospinal fluid leaks in high – risk patients. J Craniofac Surg. 2009; 20: 743-7. 20. Hutter G, von FS, Sailer MH, Schulz M, Mariani L. Risk factors for postoperative CSF leakage after ele-ctive craniotomy and the efficacy of fleece-bound tissue sealing against dural suturing alone: a randomized con-trolled trial. J Neurosurg. 2014; 121: 735-44. 21. Walcott BP, Neal JB, Sheth SA, Kahle KT, Eskandar EN, Coumans JV, et al. The incidence of complications in elective cranial neurosurgery associated with dural closure material. J Neurosurg. 2014; 120: 278-84. 22. Agarwal A, Varma A, Sarkar C. Histopathological cha-nges following the use of biological and synthetic glue for dural grafts: an experimental study. Br J Neurosurg. 1998; 12: 213-6.
23. Shermak MA, Wong L, Inoue N, Crain BJ, Im MJ, Chao EY, et al. Fixation of the craniofacial skeleton with butyl-2-cyanoacrylate and its effects on histotoxi-city and healing. Plast Reconstr Surg. 1998; 102: 309-18.